Clinical Trial Update: Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating oral arsenic (arsenic trioxide) for low-risk myelodysplastic syndromes is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Oral Arsenic (ATO) (arsenic trioxide)

Snippet

Sponsor: Groupe Francophone des Myelodysplasies | Conditions: Low-risk Myelodysplastic Syndromes | Phase 1 | Status: RECRUITING